Mindset Pharma Announces Preclinical Results Demonstrating Superior Efficacy, Safety and Shorter Duration of Action Across Multiple Next Generation Psychedelic Drug Families
Is this novel compound superior to natural psilocybin?
Mindset Pharma (MSET) revealed preclinical research suggesting that its novel psilocybin/psilocin analogs are more effective and faster acting than psilocybin, making them ideal for use in clinical settings.
An in vitro study (a study on cells in a petri dish) showed that the novel compounds had 5-10 times the effect on serotonin 5-HT2A receptors as psilocybin, which was verified by testing on mice. The half-life of the compound was less than half of psilocybin’s, which would make psychedelic therapy sessions much more efficient.